Literature DB >> 16554451

Population pharmacokinetics of oxycodone in children 6 months to 7 years old.

Ahmed El-Tahtawy1, Hannu Kokki, Bruce E Reidenberg.   

Abstract

Young children are often undertreated for pain. One barrier to effective pain treatment is understanding the pharmacokinetic behavior of analgesics in this age group. Oxycodone is a commonly prescribed opioid for severe pain, yet little is known about its pharmacokinetics in young children. This article used population pharmacokinetic modeling to synthesize pharmacokinetic data from several studies into a model. A single population model that described the observed pharmacokinetics was developed. The combined data were best described with a 2-compartment linear model with different first-order absorption rates depending on route of administration. Weight was found to significantly influence both clearance (CL) and volume of distribution (Vd). The following model adequately describes the population pharmacokinetic profile of oxycodone where absolute bioavailability (F) is estimated for each administration route: CL/F=55x(body weight/70)0.87; V/F=86x(body weight/70)1.16. The interindividual coefficients of variation in CL and Vd were 20.2 and 19.7%, respectively. This finding confirms that the allometric scaling using the above model explained most of the variability in exposure observed among children. This model confirms using a weight-based dose for oxycodone without adjustment for age between 6 months and 7 years and is valuable for evaluating dosing schedules and dosing routes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554451     DOI: 10.1177/0091270006286433

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

1.  What is the right dose for children?

Authors:  Massimo Cella; Catherijne Knibbe; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.

Authors:  Iftekhar Mahmood; Million A Tegenge
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

4.  Oxycodone overdose in the pediatric population: case files of the University of Massachusetts Medical Toxicology Fellowship.

Authors:  Katherine L Boyle; Christopher D Rosenbaum
Journal:  J Med Toxicol       Date:  2014-09

5.  Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.

Authors:  Antti Liukas; Kristiina Kuusniemi; Riku Aantaa; Petri Virolainen; Mikko Neuvonen; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

Review 6.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

7.  Population pharmacokinetics and analgesic potency of oxycodone.

Authors:  Byung-Moon Choi; Yong-Hun Lee; Sang-Mee An; Soo-Han Lee; Eun-Kyung Lee; Gyu-Jeong Noh
Journal:  Br J Clin Pharmacol       Date:  2016-09-29       Impact factor: 4.335

8.  Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.

Authors:  Merja Kokki; Marja Heikkinen; Pyry Välitalo; Heidi Hautajärvi; Juho Hokkanen; Hanna Pitkänen; Ulla Sankilampi; Veli-Pekka Ranta; Hannu Kokki
Journal:  Br J Clin Pharmacol       Date:  2016-12-05       Impact factor: 4.335

9.  The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.

Authors:  Chenguang Wang; Karel Allegaert; Mariska Y M Peeters; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 10.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.